×

EpiPen rival will return to market next year

2:05 PM ET Wed, 26 Oct 2016

Irina Koffler, Mizuho Securities, discusses why she has a buy rating on Mylan even as the news that the company's EpiPen will face more competition with the Auvi-Q auto-injector returning to the market.